Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRK6 | P43250 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.31 |
| ▸ | CA2 | P00918 | 6/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887317 | 0.89 | GSK3B (0.49) | GSK3BADKTSHRGRK6CA1 | |
| SCHEMBL5697584 | 0.89 | GSK3B (0.49) | GSK3BADKTSHRGRK6CA1 | |
| SCHEMBL5953292 | 0.89 | GSK3B (0.49) | GSK3BADKTSHRGRK6CA1 | |
| SCHEMBL6887561 | 0.87 | GSK3B (0.39) | GSK3BADKTSHRGRK6CA1 | |
| SCHEMBL6888305 | 0.87 | GSK3B (0.38) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6882003 | 0.87 | GSK3B (0.38) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6888278 | 0.86 | GSK3B (0.38) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6884997 | 0.84 | GSK3B (0.37) | GSK3BADKTSHRPDE5A | |
| SCHEMBL6886373 | 0.83 | GSK3B (0.36) | GSK3BADKTSHR | |
| SCHEMBL6880579 | 0.82 | TK2 (0.37) | GSK3BADKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |